Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.002 | 0.0483 | 0.0483 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0.0483 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.002 | 0.0483 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.002 | 0.0483 | 0.5 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.0483 | 0.5 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.0742 | 0.0742 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.002 | 0.0483 | 0.0483 |
Echinococcus granulosus | zinc finger protein | 0.0019 | 0.0341 | 0.0341 |
Schistosoma mansoni | ap endonuclease | 0.002 | 0.0483 | 0.0483 |
Echinococcus multilocularis | zinc finger protein | 0.0019 | 0.0341 | 0.0341 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.002 | 0.0483 | 0.5 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.0742 | 0.0742 |
Brugia malayi | Bromodomain containing protein | 0.0074 | 0.7832 | 0.7722 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.002 | 0.0483 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0484 | 0.0484 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.002 | 0.0483 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.0483 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.002 | 0.0483 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.002 | 0.0483 | 0.0483 |
Loa Loa (eye worm) | PHD-finger family protein | 0.002 | 0.0484 | 0.0484 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2552 | 0.2552 |
Toxoplasma gondii | exonuclease III APE | 0.002 | 0.0483 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.2552 | 0.2552 |
Schistosoma mansoni | bromodomain containing protein | 0.0062 | 0.6248 | 0.6248 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.002 | 0.0483 | 0.5 |
Brugia malayi | PHD-finger family protein | 0.0024 | 0.1062 | 0.0608 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.0742 | 0.0742 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.002 | 0.0483 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.002 | 0.0483 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.002 | 0.0483 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.007 | 0.7254 | 0.7254 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0059 | 0.5764 | 0.5764 |
Schistosoma mansoni | zinc finger protein | 0.0019 | 0.0341 | 0.0341 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.3459 | 0.3459 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.3201 | 0.3201 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.2881 | 0.2881 |
Brugia malayi | Bromodomain containing protein | 0.0038 | 0.2872 | 0.251 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.002 | 0.0483 | 0.0483 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.002 | 0.0483 | 0.5 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0017 | 0.0083 | 0.0083 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0059 | 0.5764 | 0.5764 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Antibacterial activity against Escherichia coli at 1 mg/ml after 24 hrs by agar dilution method | ChEMBL. | 19552984 | |
IC50 (binding) | > 200 uM | Inhibition of mushroom tyrosinase | ChEMBL. | 19552984 |
Inhibition (binding) | = 14.3 % | Inhibition of mushroom tyrosinase at 200 uM | ChEMBL. | 19552984 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.